At the recent UBS conference, Macaluso said that the company owns a valuable treasure chest of over 100 compounds they are developing as needed.
Additionally, Ampio is advancing NCE001, an exciting new class of cancer treatment drug that has shown amazing in vitro results. NCE001 has the potential to surprise very big.
Ampio also developed a revolutionary diagnostic called, "Oxidation Reduction Potential", "ORP", that has the potential to save millions of lives and billions of dollars.
Aegis Capital has a price target of $12 but that seems conservative given their pipeline and its' mature stage of development. Ampio's financial filings indicate about $17 million in cash that should be enough to last until 2014.